The use of modern dopamine partial agonists in bipolar depression: is the evidence sound?

References

• Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010;18(3):143–157.
   PubMed Web of Science ®Google Scholar
• Mitchell PB, Goodwin GM, Johnson GF, et al. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord. 2008;10(1 Pt 2):144–152.
   PubMed Web of Science ®Google Scholar
• Diaz AP, Fernandes BS, Quevedo J, et al. Treatment-resistant bipolar depression: concepts and challenges for novel interventions. Braz J Psychiatry. 2021;S1516–S44462021005016202.
   Google Scholar
• Soares JC. Recent advances in the treatment of bipolar mania, depression, mixed states, and rapid cycling. Int Clin Psychopharmacol. 2000;15(4):183–196.
   PubMed Web of Science ®Google Scholar
• Sachs GS. Unmet clinical needs in bipolar disorder. J Clin Psychopharmacol. 2003;23(3 Suppl 1):S2–S8.
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
   PubMed Web of Science ®Google Scholar
• Seroquel XR (quetiapine fumarate extended-release) [package insert]. Wilmington, Del, AstraZeneca Pharmaceuticals, 2013.
   Google Scholar
• Latuda (lurasidone HCL) tablets [package insert]. Marlborough, Mass, Sunovion Pharmaceuticals, 2017.
   Google Scholar
• Zyprexa (olanzapine) [package insert]. Indianapolis, Eli Lilly and Company, 2009.
   Google Scholar
• Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Biol Psychiatry. 2000;48(6):558–572.
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry. 1995;152(8):1130–1138.
   PubMed Web of Science ®Google Scholar
• McGirr A, Vöhringer PA, Ghaemi SN, et al. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. Lancet Psychiatry. 2016;3(12):1138–1146.
   PubMed Web of Science ®Google Scholar
• Amerio A, Russo D, Miletto N, et al. Polypharmacy as maintenance treatment in bipolar illness: a systematic review. Acta Psychiatr Scand. 2021;144(3):259–276.
   PubMed Web of Science ®Google Scholar
• Agency of Healthcare Research and Quality. Treatment for bipolar disorder in adults: A systematic review; comparative effectiveness review number 208. AHRQ Publication No. 18-EHC012-EF. 2018.
   Google Scholar
• Jauhar S, Young AH. Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy. Int J Bipolar Disord. 2019;7(1):10.
   PubMed Web of Science ®Google Scholar
• Citrome L. The ABC's of dopamine receptor partial agonists – aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(11):1211–1220.
   PubMed Web of Science ®Google Scholar
• Thase ME, Bowden CL, Nashat M, et al. Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms. Int J Psychiatry Clin Pract. 2012;16(2):121–131.
   PubMed Web of Science ®Google Scholar
• Dunn RT, Stan VA, Chriki LS, et al. A prospective, open-label study of aripiprazole mono- and adjunctive treatment in acute bipolar depression. J Affect Disord. 2008;110(1–2):70–74.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Dago PL, Straus JL, et al. Aripiprazole augmentation for treatment-resistant bipolar depression: sustained remission after 36 months. J Clin Psychopharmacol. 2007;27(3):304–305.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Gilmer WS, Fleck J, et al. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):574–577.
   PubMed Web of Science ®Google Scholar
• McElroy SL, Suppes T, Frye MA, et al. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. J Affect Disord. 2007;101(1–3):275–281.
   PubMed Web of Science ®Google Scholar
• Yatham LN. A clinical review of aripiprazole in bipolar depression and maintenance therapy of bipolar disorder. J Affect Disord. 2011;128(Suppl 1):S21–S8.
   PubMed Web of Science ®Google Scholar
• Kemp DE, Calabrese JR, Eudicone JM, et al. Predictive value of early improvement in bipolar depression trials: a post-hoc pooled analysis of two 8-week aripiprazole studies. Psychopharmacol Bull. 2010;43(2):5–27.
   Google Scholar
• Quante A, Zeugmann S, Luborzewski A, et al. Aripiprazole as adjunct to a mood stabilizer and citalopram in bipolar depression: a randomized placebo-controlled pilot study. Hum Psychopharmacol. 2010;25(2):126–132.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(03):371–378.
   PubMed Web of Science ®Google Scholar
• Earley W, Burgess MV, Rekeda L, et al. Cariprazine treatment of bipolar depression: a randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry. 2019;176(6):439–448.
   PubMed Web of Science ®Google Scholar
• Earley WR, Burgess M, Rekeda L, et al. A pooled post hoc analysis evaluating the safety and tolerability of cariprazine in bipolar depression. J Affect Disord. 2020;263:386–395.
   PubMed Web of Science ®Google Scholar
• Brown ES, Khaleghi N, Van Enkevort E, et al. A pilot study of brexpiprazole for bipolar depression. J Affect Disord. 2019;249:315–318.
   PubMed Web of Science ®Google Scholar
• Mohr P, Masopust J, Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? Front Psychiatry. 2021;12:781946.
   PubMed Web of Science ®Google Scholar
• Ashok AH, Marques TR, Jauhar S, et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment. Mol Psychiatry. 2017;22(5):666–679.
   PubMed Web of Science ®Google Scholar
• Argyropoulos SV, Nutt DJ. Anhedonia revisited: is there a role for dopamine-targeting drugs for depression? J Psychopharmacol. 2013;27(10):869–877.
   PubMed Web of Science ®Google Scholar
• Mah L, Zarate CA, Jr, Nugent AC, et al. Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int J Neuropsychopharmacol. 2011;14(4):545–551.
   PubMed Web of Science ®Google Scholar
• Lammers CH, Diaz J, Schwartz JC, et al. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry. 2000;5(4):378–388.
   PubMed Web of Science ®Google Scholar
• D'haenen HA, Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 1994;35(2):128–132.
   PubMed Web of Science ®Google Scholar
• Shah PJ, Ogilvie AD, Goodwin GM, et al. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med. 1997;27(6):1247–1256.
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59:60–64.
   PubMed Web of Science ®Google Scholar
• Erfurth A, Michael N, Stadtland C, et al. Bupropion as add-on strategy in difficult-to-treat bipolar depressive patients. Neuropsychobiology. 2002;45(1):33–36.
   PubMed Web of Science ®Google Scholar
• Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997;12:S7–S14.
   PubMed Web of Science ®Google Scholar
• Carnicella S, Drui G, Boulet S, et al. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits. Transl Psychiatry. 2014; 4:e401.
   PubMed Web of Science ®Google Scholar
• Marder S, Laszlovszky I, Szalai E, et al. Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition. Eur Neuropsychopharmacol. 2016;26:S550.
   Web of Science ®Google Scholar
• Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb Exp Pharmacol. 2012; 213:167–210.
   Google Scholar
• Nakajima S, Gerretsen P, Takeuchi H, et al. The potential role of dopamine D3 receptor neurotransmission in cognition. Eur Neuropsychopharmacol. 2013;23(8):799–813.
   PubMed Web of Science ®Google Scholar
• Papp M, Gruca P, Lasoń-Tyburkiewicz M, et al. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25(5-6):567–574.
   PubMed Web of Science ®Google Scholar
• Román V, Gyertyán I, Sághy K, et al. Cariprazine (RGH-188), a D3-preferring dopamine D3/D2 receptor partial agonist antipsychotic candidate demonstrates antiabuse potential in rats. Psychopharmacology. 2013;226(2):285–293.
   PubMed Web of Science ®Google Scholar